Skip to main content
SpringerLink
Log in

Desirable Lipoprotein Parameters in Early Drug Trials

  • Conference paper
Drugs Affecting Lipid Metabolism

Part of the book series: Proceedings in Life Sciences ((LIFE SCIENCES))

  • 209 Accesses

Abstract

Lipid-lowering drugs may be tested very early in patients, in view of the overall “normality” of these subjects, aside from their specific biochemical disorder. Although current modalities for the early evaluation of new drug products require administration to “healthy” volunteers, it is becoming more and more common to carry out early testing in “healthy” subjects with elevated plasma lipid levels. In view of the high expectation for new drug products, active in primary hyperlipoproteinemias (The Lipid Research Clinics 1984), we personally consider as feasible and advisable to carry out the Phase I evaluation of new drugs for hyperlipidemia in patients. These should possibly never have received drug treatments or, in some cases, should be evaluated after stopping treatment with specific products (e.g. anion-binding resins).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB (1979) Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet i:901–903

    Article  Google Scholar 

  • Baggio G, Briani G, Fellin R, et al. (1979) Effect of tiadenol on the concentration and composition of serum lipoproteins in familial hypercholesterolemia. Artery 5:486–498

    Google Scholar 

  • Bengtsson G, Olivecrona T (1980) Lipoprotein lipase: some effects of activator proteins. Eur J Biochem 106:549–555

    Article  PubMed  CAS  Google Scholar 

  • Carlson LA, Kolmodin-Hedman B (1977) Hyper-α-lipo-proteinemia in men exposed to chlorinated hydrocarbon pesticides. Acta Med Scand 201:375–376

    Article  PubMed  CAS  Google Scholar 

  • Deckelbaum RJ, Granot E, Oschry Y, et al. (1984) Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4:225–231

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg S (1985) High density lipoprotein metabolism. J Lipid Res 25:1017–1058

    Google Scholar 

  • Franceschini G, Poli A, Catapano A, et al. (1981) Pharmacological studies on tiadenol in type IV patients — evidence for a mechanism of action different from other lipid lowering drugs. Atherosclerosis 40:245–255

    Article  PubMed  CAS  Google Scholar 

  • Franceschini G, Bondioli A, Mantero M, et al. (1982) Increased apoprotein B in very low density lipoproteins of patients with peripheral vascular disease. Arteriosclerosis 2:74–80

    Article  PubMed  CAS  Google Scholar 

  • Franceschini G, Sirtori M, Gianfranceschi G, et al. (1985) Reversible increase of the apo CII/CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Artery 12:363–381

    PubMed  CAS  Google Scholar 

  • Gaddi A, Descovich GC, Noseda S, et al. (1984) Controlled evaluation of pantethine, a natural hypolipidemic compound in patients with different forms of hyperlipoproteinemia. Atherosclerosis 50:73–83

    Article  PubMed  CAS  Google Scholar 

  • Gibson JC, Rubinstein A, Brown WV (1984) Precipitation of apo E-containing lipoprotein by precipitation reagents for apolipoprotein B. Clin Chem 30:1784–1788

    PubMed  CAS  Google Scholar 

  • Gidez LI, Miller GJ, Burstein M, Eder HA (1979) Analysis of plasma HDL subclasses by a precipitation procedure. In: Rep HDL Methodology Worksh, NIH Publ 82–1661, Bethesda, MD, p 328

    Google Scholar 

  • Gugler R (1978) Clinical pharmacokinetics of hypolipidemic drugs. Clin Pharmacokinet 3:425–439

    Article  PubMed  CAS  Google Scholar 

  • Kane JP, Sata T, Hamilton RL, et al. (1975) Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest 56:1622–1634

    Article  PubMed  CAS  Google Scholar 

  • Knopp RH, Ginsberg J, Albert JJ, et al. (1985) Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34:642–650

    Article  PubMed  CAS  Google Scholar 

  • Kritchevsky D, Tepper SA, Czarnecky SK, Story JA (1979) Influence of tiadenol, bis (hydroxyethylthio) 1.10 decane, on cholesterol metabolism in rats. Pharmacol Res Commun 11:475–482

    Article  PubMed  CAS  Google Scholar 

  • The Lipid Research Clinics Coronary Primary Prevention Trial Results (1984) J Am Med Assoc 251:351–374

    Article  Google Scholar 

  • Mahley RW (1983 Apolipoprotein E and cholesterol metabolism. Klin Wochenschr 61:225–232

    Article  PubMed  CAS  Google Scholar 

  • Mattson FM, Grundy SM (1985) Comparison of effects of dietary saturated, monounsaturated and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res 26:199–202

    Google Scholar 

  • Nikkilä EA, Huttunen JK, Ehnholm C (1977) Effect of Clofibrate on post-heparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 26:179–186

    Article  PubMed  Google Scholar 

  • Pan HY, Willard DA, Funker PT, McKinstry DN (1986) The clinical pharmacology of SQ 31,000 (CS-514) in healthy subjects. IX Int Symp Drugs Affecting Lipid Metabolism. Florence, Italy, October 22–25

    Google Scholar 

  • Saku K, Gartside PS, Hynd A, Kashyap ML (1986) Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 75:1702–1712

    Article  Google Scholar 

  • Schmidt SB, Wasserman AG, Muesing RA, et al. (1985) Lipoprotein and apolipoprotein levels in angiographically defined coronary atherosclerosis. Am J Cardiol 55:1459–1462

    Article  PubMed  CAS  Google Scholar 

  • Schmitz G, Assmann G (1982) Isolation of human serum HDLj by zonal ultracentrifugation. J Lipid Res 23:903–910

    PubMed  CAS  Google Scholar 

  • Schonfeld G, George PK, Miller J, Reilly P, Witztum J (1979) Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28:1001–1010

    Article  PubMed  CAS  Google Scholar 

  • Simpson HS, Ballantyne FC, Packard CJ, Morgan HG, Shepherd J (1982) High-density lipoprotein subfractions as measured by differential polyanionic precipitation and rate zonal ultracentrifugation. Clin Chem 28:2040–2043

    PubMed  CAS  Google Scholar 

  • Sirtori CR, Franceschini G (1984) Drug effects on HDL. In: Miller NE, Miller GJ (eds) Clinical and metabolic aspects of high-density lipoproteins. Elsevier, Amsterdam, p 341

    Google Scholar 

  • Sirtori CR, Montanari G, Gianfranceschi G, et al. (1985) Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients. Eur J Clin Pharmacol 28:619–629

    Article  PubMed  CAS  Google Scholar 

  • Sirtori CR, Tremoli E, Gatti E, et al. (1986) Controlled evaluation of fat intake in the Mediterranean diet: comparative activities of olive oil and corn oil on plasma lipids and platelets in high-risk patients. Am J Clin Nutrit 44:635–642

    PubMed  CAS  Google Scholar 

  • Sirtori CR, Franceschini G, Gianfranceschi G, et al. (1987) Effects of gemfibrozil on plasma lipoprotein/apolipoprotein distribution and platelet reactivity in hypertriglyceridemic patients. J Lab din Med (in press)

    Google Scholar 

  • Sniderman A, Shapiro S, Marpole D, et al. (1980) Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins) Proc Natl Acat Sci USA 77:604–608

    Article  CAS  Google Scholar 

  • Wallenstein S, Fischer AC (1977) The analysis of the two-period repeated measurements cross-over design with application to clinical trials. Biometrics 33:261–272

    Article  PubMed  CAS  Google Scholar 

  • Warnick GR, Albers JJ (1978) A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65–76

    PubMed  CAS  Google Scholar 

  • Warnick GR, Cheung MC, Albers JJ (1979) Comparison of current methods for high-density lipoprotein cholesterol quantitation. Clin Chem 25:596–604

    PubMed  CAS  Google Scholar 

  • Warnick GR, Albers JJ, Leary ET (1980) HDL cholesterol: results of interlaboratory proficiency test. Clin Chem 26:169–170

    PubMed  CAS  Google Scholar 

  • Warnick GR, Benderson JM, Albers JJ (1983) Interlaboratory proficiency survey of high-density lipoprotein cholesterol measurement. Clin Chem 29:516–519

    PubMed  CAS  Google Scholar 

  • Witztum JL, Dillingham MA, Giese W, et al. (1980) Normalization of triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol. N Engl J Med 30:907–914

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, 20129, Milano, Italy

    A. Bondioli

  2. Divisione Medica Vergani, Ospedale di Niguarda Ca’ Granda, 20129, Milano, Italy

    A. Bondioli

Authors
  1. C. R. Sirtori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bondioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Pharmacy, University of Milan, Via Balzaretti 9, 20133, Milan, Italy

    Rodolfo Paoletti (Dean) (Dean)

  2. The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, 19104, USA

    David Kritchevsky (Associate Director) (Associate Director)

  3. 238 Chatham Way, West Chester, PA, 19380, USA

    William L. Holmes

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Sirtori, C.R., Bondioli, A. (1987). Desirable Lipoprotein Parameters in Early Drug Trials. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71702-4_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71704-8

  • Online ISBN: 978-3-642-71702-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation